Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074802 · ClinicalTrials.gov registry record · Phase 3
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
A Phase 3 study of Social Anxiety Disorder, sponsored by Temple University.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT00074802 is a Phase 3 study of Social Anxiety Disorder that has completed, run by Temple University. The registered enrollment target is 150 participants, roughly in line with the 155-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT00074802, a Phase 3 study of Social Anxiety Disorder, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will examine whether the addition of cognitive behavioral therapy can improve the efficacy of the medication paroxetine (Paxil®) in treating individuals with social anxiety disorder. Patients with social anxiety disorder will undergo a 12-week open trial with paroxetine. Those who complete the open trial having achieved only partial response will be randomized to receive cognitive behavioral therapy (CBT) in addition to paroxetine or to continue on paroxetine alone for an additional 16 weeks.
Conditions Studied
Interventions
- DRUG Paroxetine
- BEHAVIORAL Cognitive behavioral therapy (CBT)
Study Locations (2)
New York
- New York State Psychiatric Institute Anxiety Disorders Clinic - New York
Pennsylvania
- Adult Anxiety Clinic of Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074802
The ClinicalTrials.gov registry entry for NCT00074802 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 155-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Paroxetine is the first listed.
NCT00074802 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00074802 about?
NCT00074802 is a clinical study titled "Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder". This study will examine whether the addition of cognitive behavioral therapy can improve the efficacy of the medication paroxetine (Paxil®) in treating individuals with social anxiety disorder. Patients with social anxiety disorder will undergo a 12-week open trial with paroxetine. Those who complet...
What is the current status of trial NCT00074802?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2003-12. Estimated completion is 2008-05.
What conditions does trial NCT00074802 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT00074802?
The interventions under investigation include: Paroxetine (DRUG), Cognitive behavioral therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00074802?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074802 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
COMPLETED · Phase 3
-
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.